STANDARD PRACTICES
Vaccine safety: Modern medicine meets the manual supply chain
by Karen Conway, Vice President, Healthcare Value, GHX P
resident Franklin D. Roosevelt described Dec. 7, 1941, to an emergency Joint Session of Congress as “a date which will live on in infamy” following the horrendous attack on Pearl
Harbor. Seventy-nine years and one day later, Dec. 8, 2020, made its mark in the history books as a 90-year-old grandmother in the nited ingdom (..) became the fi rst person in the world to receive the Pfi erioTech vaccine to fi ght off COVID-19. p to four million of her country men and women are expected to receive similar inoculations by the end of January. Meanwhile, on the same day, the U.S. Food and Drug Administration announced it determined the same vaccine has met the prescribed success criteria, a necessary precursor for the Pfi erioTech vaccine to receive emergency use authoriation in the .. U.K. Secretary of of State for Health and Social Care Matt Han-
cock heralded the start of the vaccination program as the start of the fi ghtback against our common enemy, the coronavirus. In many ways, it also marks the start of one of the supply chains greatest logistical challenges as a multitude of stakeholders work to ensure the safe and effective delivery of the vaccine to billions of people around the world. ouve heard the stories about the challenges of keeping some
of the vaccines, including the Pfi erioTech, at ultra-cold temperatures. The Pfi erioTech must be stored long-term at minus 9 degrees ahrenheit or below, a capability that even many of the most sophisticated health systems do not have. nother promising vaccine from Moderna also needs to be kept cold, but at less extreme temperatures, while others in the pipeline have even fewer requirements. one of this overcomes the fact that the different vaccines come with different requirements, from cold chain to the number of doses required, all of which introduces more variation into the system. And as readers of tandard Practices appreciate, variation is the enemy of quality. urther, within days in ovember, we received two ominous warnings about cyber criminals attempting to disrupt the cold chain and render the vaccines ineffective, and the likelihood of organied crime stealing the highly valuable vaccines andor selling fake doses.
The good news is we have the technology to overcome these challenges. The bad news is the use of that technology (e.g., bar codes and scanners) is limited, and the ability to share data across multiple parties, i.e., interoperability, remains a struggle. Couple that with the fact that the ability to secure vaccines through the system, whether to monitor the cold chain or to prevent counter- feit products, depends on the actions of a multitude of players, from manufacturers and distributors to hospitals and state and local health departments. ets start with interoperability. e are making progress on the regulatory front, with new rules going into effect Jan. 1, 2021 that require hospitals and payers to share data across organiations and with patients. ut hospitals, even before facing the challenges of COVID-19, have argued that compliance is diffi cult due to cost and technological capabilities. The .. Drug upply Chain ecurity ct (DC) was passed
in 2013 to help address the counterfeit issue, but all medicines are not required to be tracked at the unit level until 2023. The global standards organiation, 1, also has developed a data matrix confi guration that can integrate the use of sensors to monitor temperature with bar codes, which would make it possible to address both the cold chain and counterfeit issues. t this point, there are no requirements to include bar codes at the primary (or vial) level. Instead, bar codes will be on the secondary packaging, which could hold hundreds of vaccines. ccording to the orld ealth Organiation, some manufac-
turers have argued that requiring bar codes at the primary pack- aging level would be both time consuming and costly, especially given that many sites where the vaccines will be given do not have the scanning capability in place. Others have countered that traceability of the vaccines will be much more diffi cult if those secondary packages need to be opened for distribution to rural and remote locations where there simply are not enough people to warrant sending the larger quantity packages. Instead, the ability to comply with cold chain requirements and to track which patients received which vaccine will be up to the individual players in the vaccine supply chain. The vials will have informa- tion that can be recorded manually, but as we all know, manual documentation is error prone. ow then can we be confi dent that we are capturing informa-
Image by Willfried Wende from Pixabay
tion accurately to ensure the effectiveness of the vaccines by complying with cold chain requirements monitor for potential adverse effects of any of the vaccines or specifi c batches or lots and guarantee that patients who require a second dose do indeed get the second dose of the same vaccine These are all critical issues to achieve the promise of what has been nothing short of a modern medical miracle around the speed of vaccine develop- ment. s a friend of mine in the vaccine manufacturing space asked If we can create effective vaccines in less than a year, why cant we take the time to ensure the integrity of the vaccines by applying barcodes to support traceability HPN
50 January 2021 • HEALTHCARE PURCHASING NEWS •
hpnonline.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58
